learn more about crypto Top Block

A new generation of quantum chips has achieved a breakthrough in error correction capability. According to a paper published in Nature magazine on the 10th, Google's latest generation of quantum chips has achieved a breakthrough in error correction capability, that is, the error is suppressed below a critical threshold. This quantum error correction function is considered as a necessary condition to realize the practical application of quantum computing in the future. After the performance of the chip is expanded, it may be able to promote the operation requirements of large-scale fault-tolerant quantum computing.Navigation warning! Sea shooting test in the southern Yellow Sea, according to the website of China Maritime Safety Administration, Lianyungang Maritime Safety Administration issued a navigation warning. From 8: 00 to 14: 00 on December 11, some sea areas in the southern Yellow Sea were fired with live ammunition, and it was forbidden to enter.CITIC Securities: The logic of "grabbing exports" is expected to support the short-term performance of China's exports. According to the CITIC Securities Research Report, in November, China's exports maintained a certain growth rate, exports to emerging markets maintained a high growth rate, and exports of mechanical and electrical products performed brilliantly. In the short term, both CCFI index and SCFI index are on the rise, and the logic of "grabbing exports" is expected to support the short-term performance of China's exports. In the long run, if the United States imposes tariffs on China, China's export performance may be dragged down. However, based on the analysis of the import share structure of the United States, the European Union, Vietnam, Mexico and other economies, we can see that the current pattern of China's trade diversification has improved compared with the last round of Sino-US trade friction, and the trade between emerging markets and China has become closer and closer. The imposition of tariffs by the United States on China may affect the bilateral trade between China and the United States more, and domestic enterprises going to sea and re-exporting trade may still be effective ways to hedge the impact of US tariffs on China.

Guotai Junan: The bottom of China stock market has appeared, and the conditions for a "transformation bull" are taking shape. Guotai Junan Securities recently released the prospect of China's equity investment strategy in 2025, and the bottom of China stock market has appeared, and the conditions for a "transformation bull" are taking shape. After a long period of continuous adjustment, pessimistic expectation and clear microstructure, it is a prerequisite for the stock market to have valuation flexibility. The positive change of decision-makers' attitude towards reversing the economic situation and supporting the capital market is an important cornerstone for revising long-term expectations and getting rid of "bear market thinking" and raising the bottom of the stock market. The reform of the capital market will improve shareholders' returns, and resolving debts, promoting reform and stabilizing asset prices are expected to constitute the new "three arrows" of China's economic development, and the transformation bull of China's stock market is taking shape.New World Development sold Artisan Lab in Kowloon, Hong Kong for HK$ 620 million. Sing Tao Daily quoted an unnamed insider as saying that New World Development sold Artisan Lab in San Po Kong, Kowloon for HK$ 620 million. This 22-storey building was completed in 2022, with a floor area of about 120,000 square feet.Kathy Hochul, the governor of New York, said that a governor's arrest warrant would be issued to the suspect who murdered the CEO of United Health Insurance.

Caoji Group seeks to raise up to HK$ 138 million through Hong Kong IPO. According to the announcement of the Hong Kong Stock Exchange, Caoji Group will issue about 33.3 million shares at a price range of HK$ 3.75 to HK$ 4.15 per share. The company may raise up to HK$ 138 million (US$ 17.8 million) and is expected to start listing on December 19th.Sagitar Juchuang will raise HK$ 277.5 million by placing shares. According to the announcement of the Hong Kong Stock Exchange, the robotics company Sagitar Juchuang agreed to place 10 million new shares at a price of HK$ 27.75 per share. The matching price is about 8% lower than Tuesday's closing price of HK$ 30.15 per share. The proceeds from the placement of shares will be mainly used for research and development, enhancing business development capabilities in overseas markets and exploring potential strategic partnership or alliance opportunities.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.